JenKem PEGylation ReagentsJenKem Technology provides high quality linear reactive polyethylene glycol (PEG) products for PEGylation, with high purity, low polydispersity, and low to no diol content.

JenKem Technology’s linear monofunctional PEG derivatives have a reactive group at one end of the PEG polymer chain, while the other end is capped with a methoxy group, benzyl group, or a sugar group. JenKem Technology provides linear methoxy PEG derivatives for amine PEGylation, thiol PEGylation, N-terminal PEGylation, and C-terminal PEGylation, for various applications [1]. Linear monofunctional PEG derivatives have the general structure: CAP―PEG―X, where X is the functional reactive group and CAP can be either a methoxy group, a benzyl group, or a targeting monosaccharide molecule such as glucose and galactose.JenKem PEG Quality

Linear monofunctional PEG products with molecular weights and functional groups not listed in our online catalog may be available by custom synthesis. Please inquire at about pricing and availability.

JenKem Technology provides GMP grade PEG derivatives and bulk orders via custom synthesis, offering the opportunity to match customers’ special quality requirements. JenKem Technology is capable of development and synthesis of a wide range of GMP PEG derivatives starting at 200g up to 40 kg or greater batches, under ISO 9001 and ISO 13485 certified quality management system, following ICH Q7A guidelines. For inquiries on cGMP production of PEG derivatives and PEGylation services please contact us at

For global distribution, please visit link. To order directly from JenKem Technology:

Linear NHS mPEGs with Cleavable Linker
≥ 95% Methoxy PEG Succinimidyl Succinate is a degradable PEG linker reacting with the amino group of lysine(s) on proteins or other biologics, such as the amines on the active ingredients of Adagen®, Pegademase, PEG-adenosine deaminase, PEG aspargase, PEG-L-asparaginase, and related biosimilars, at pH 7-8, while the ester linkage is cleaved under regular ester cleaving reaction conditions.[2,3]
≥ 95% Methoxy PEG Succinimidyl Glutarate is a degradable PEG linker that reacts with the amino group of lysine(s) on proteins or other biologics at pH 7-8, while the ester linkage is cleaved under regular ester cleaving reaction conditions.
Linear Monosaccharide NHS PEGs
≥ 90% Galactose PEG NHS reacts with amino group of lysine(s) at room temperature in under 1hr, at pH 7-8. The presence of the targeting galactose monosaccharide increases significantly the selectivity of the PEGylation reaction. [5]
≥ 90% Glucose PEG NHS reacts with amine group of lysine(s) at room temperature in less than 1hr, at pH 7-8. The presence of the targeting sugar group (Glucose) increases significantly the selectivity of the PEGylation reaction. [5, 6]
Linear Methoxy NHS mPEGs with Stable Linker
≥ 95% Methoxy PEG Succinimidyl Carboxymethyl Ester reacts with the amine group of lysine(s) at room temperature in less than 1hr at pH 7-8. Shorter hydrolysis half life of M-PEG-SCM ensures maximum selectivity towards most sterically available amine groups. [7-9, 46, 47]
≥ 95% Methoxy PEG Succinimidyl Propionate (Methoxy PEG Succinimidyl Propanoate) reacts with the amine group of lysine(s, such as amines on the active ingredients of Somavert®, PEG-HGH antagonist, Pegvisomant, PEG growth hormone B2036, pegylated granulocyte colony stimulating factor MAXY-G34 ( PEG-CSF MAXY-G34), or Puricase PEG-uricase, Pegloticase, or Krystexxya®, and related biosimilars. [12]
≥ 95% Methoxy PEG Succinimidyl Butanoate reacts with the amine group of lysine(s), such as the amines on active ingredients of Mircera®, or Peg-epo biosimilars, at room temperature at pH 7-8. Methoxy PEG Succinimidyl Butanoate has a longer hydrolysis half-life compared with M-PEG-SCM.
≥ 95% Methoxy PEG Succinimidyl Hexanoate reacts with the amine group of lysine(s) at pH 7-8. Methoxy PEG Succinimidyl Hexanoate has a longer hydrolysis half-life compared with M-PEG-SCM and M-PEG-SBA. [10, 48, 49]
≥ 95% Methoxy PEG Succinimidyl Succinamide reacts with the amine group of lysine(s) at pH 7-8. Methoxy PEG Succinimidyl Succinamide has a longer hydrolysis half-life compared with M-PEG-SCM.[11]
≥ 90% Methoxy PEG Succinimidyl Glutaramide reacts with the amine group of lysine(s) at pH 7-8. Methoxy PEG Succinimidyl Glutaramide has a longer hydrolysis half-life compared with M-PEG-SCM. [12]
Linear Carbonate mPEGs
≥ 95% Methoxy PEG Succinimidyl Carbonate reacts with the amino group of lysine(s) on proteins or other biologics, such as the amiens present on proteins for Peg-intron, PEG-IFN, Interferon alpha 2b, Pegintron®, Redipen, Sylatron and related biosimilars. Methoxy PEG Succinimidyl Carbonate has a longer hydrolysis half-life compared with M-PEG-SCM.[4]
≥ 90% Methoxy PEG Nitrophenyl Carbonate is reactive towards the the amino group of lysine(s) on proteins or other biologics, with a longer hydrolysis half-life compared with M-PEG-SCM.
Linear Carboxyl mPEGs
≥ 95% Methoxy PEG Carboxyl (Methoxy PEG Acetic Acid, or M-PEG-COOH) is more stable than M-PEG-SCM.[16, 17, 50-52]
≥ 95% Methoxy PEG Propionic Acid (Methoxy PEG Propanoic Acid) is more stable than M-PEG-SPA.[54]
≥ 95% Methoxy PEG Butanoic Acid (Methoxy PEG Butyric Acid) is more stable than M-PEG-SBA.
≥ 95% Methoxy PEG Hexanoic Acid  is more stable than M-PEG-SHA.
Linear Methoxy PEG Amine
≥ 95% Methoxy PEG Amine. Attaches via stable linkages, such as amide, urethane, urea, secondary amine; the HCl salt form provides stability for the solid form of M-PEG-NH2 [18, 53, 55]
Linear Methoxy PEG Aldehyde
≥ 95% Methoxy PEG Aldehyde reacts with N-terminal amines, such as the N-terminal on proteins for Peg-filgastrim Peg-gsf, PEG-rhGCSF, Neulasta®, and related biosimilars, at pH 5-8 in the presence of a reducing reagent. [19-21]. Methoxy Propionaldehyde PEG with MW 20000 (M-ALD-20K) can be utilized as a PEG raw material for pegfilgrastim PEGylated biosimilars [22].
Linear Methoxy Maleimide PEGs
≥ 95% Methoxy PEG Maleimide from JenKem Technology is a thiol reactive PEG derivative selective for thiol groups on cystein side chains. Methoxy PEG Maleimide undergoes thiol PEGylation reactions with thiol-containing molecules at pH 5.0-6.5.[23-25]
Linear Methoxy Vinylsulfone PEGs
≥ 90% Methoxy PEG Vinylsulfone are high quality products for sulfhydryl PEGylation. Methoxy Vinylsulfone PEG products are special thiol PEGylation PEGs that react at high pH. [26]
Linear Methoxy Thiol PEGs
≥ 95% Methoxy PEG Thiol is a high quality activated PEG product for thiol pegylation. Methoxy PEG Thiol PEGylates the thiol groups on cysteine side chains under mild reaction conditions.[27-30]
Biodegradable M-PEG Oligopeptides
≥95% Methoxy PEG Di-Glutamic Acid. Oligopeptide PEG for micelle formation used for drug encapsulation and drug delivery
≥90% Methoxy PEG Tri-Glutamic Acid. Oligopeptide PEG for micelle formation useful in drug encapsulation and drug delivery
≥90%(Main peak wt%) PLL20K-G35-PEG2K, PEG-Poly(L-lysine), Poly(L-lysine), Graft Ratio 3.5, PLL MW 20000, PEG MW 2000 [31-35]
Click Chemistry PEGs
≥90% Methoxy PEG Alkyne. Click chemistry PEG reagent for reaction with azide groups
≥90% Methoxy PEG Azide. The azide group may be reduced to amines by hydrogenolysis. Click PEG reagent for reaction with alkynes, simple reaction conditions, high selectivity, and rapid reaction with high yield. Water can be used as the reaction solvent. [36]
Other Special mPEG Products
≥95% Methoxy PEG Hydrazide reacts with aldehydes and ketones to give stable hydrazones in a single step; it can also react with activated carboxylic acids [37]
≥90% Methoxy PEG Biotin. Avidin reactive PEG. Streptavidin reactive PEG. [38]
≥90% Methoxy PEG Silane for glass or silica surface modification and deactivation [39, 40]
≥90% Methoxy PEG Acrylate reacts with sulfhydryl groups (Michael addition reaction). Used for Vinyl polymerization or co-polymerization [41]
≥95% Methoxy PEG Phosphate. PEG reagent for surface modifications; increases water solubility. [42]
≥90% Methoxy PEG Lipoic Acid. (mPEG Thioctic Acid). High affinity for metals, useful for gold nanoparticle surface modification. [43]
≥95% Methoxy PEG DSPE mPEG phospholipid for liposome formation. [44, 45]
≥90% Methoxy PEG OA mPEG Oleic Acid lipid for liposome formation.
Linear mPEG Hydroxyl Raw Materials
≥95% ≤ 1.05-1.10
  1. Hutanu, D., et al., Recent Applications of Polyethylene Glycols (PEGs) and PEG Derivatives. Mod Chem appl, 2014, 2(132).
  2. Mastorakos, P., et al., Biodegradable DNA Nanoparticles that Provide Widespread Gene Delivery in the Brain. Small, 2015.
  3. Jain, S., et al., Combinatorial bio-conjugation of gemcitabine and curcumin enables dual drug delivery with synergistic anticancer efficacy and reduced toxicity, RSC Adv., 2014, 4, 29193-29201.
  4. Vaillard, V.A., et al., mPEG–NHS carbonates: Effect of alkyl spacers on the reactivity: Kinetic and mechanistic insights, Journal of Applied Polymer Science, 2019, 136(5):47028.
  5. He, H., et al., Bolstering cholesteryl ester hydrolysis in liver: A hepatocyte-targeting gene delivery strategy for potential alleviation of atherosclerosis, Biomaterials, 2017, 130:1-3.
  6. Drappier, C., pH-Responsive Surface Shielding By Electrostatic Adsorption of PEG Segments With Anionic Chain End, Universite Bordeaux, 2013.
  7. Rajkumar, S., et al., Multi-functional core-shell Fe3O4@Au nanoparticles for cancer diagnosis and therapy, Colloids and Surfaces B: Biointerfaces, 2019, V. 174, P. 252-259.
  8. Rompicharla, S.V., et al., Biotin functionalized PEGylated poly (amidoamine) dendrimer conjugate for active targeting of paclitaxel in cancer, International journal of pharmaceutics, 2019, 557:329-41.
  9. Gao, W., et al., Transferrin receptor-targeted pH-sensitive micellar system for diminution of drug resistance and targetable delivery in multidrug-resistant breast cancer, International Journal of Nanomedicine, 2017, 12:1047.
  10. Mesken, J., et al., Modifying plasmid-loaded HSA-nanoparticles with cell penetrating peptides–Cellular uptake and enhanced gene delivery, International journal of pharmaceutics, 2017, 522(1):198-209.
  11. Li, C., et al., Real-Time Monitoring Surface Chemistry-Dependent In Vivo Behaviors of Protein Nanocages via Encapsulating an NIR-II Ag2S Quantum Dot, ACS Nano, 2015, 9 (12), 12255-12263.
  12. Suarez, S.L., et al., Intramyocardial injection of hydrogel with high interstitial spread does not impact action potential propagation, Acta Biomaterialia, 2015, 26, P. 13-22.
  13. Pfister, D., et al., Integrated process for high conversion and high yield protein PEGylation, Biotechnol. Bioeng., 2016.
  14. Goffin V, et al., Pegvisomant Pfizer/Sensus. Curr Opin Investig Drugs, 2004, 5:463–468.
  16. Lassenberger, A., et al., Individually stabilized, superparamagnetic nanoparticles with controlled shell and size leading to exceptional stealth properties and high relaxivities. ACS Applied Materials & Interfaces, 2017.
  17. Dai, L., et al., Self-assembled PEG–carboxymethylcellulose nanoparticles/α-cyclodextrin hydrogels for injectable and thermosensitive drug delivery, RSC Advances, 2017, 7(5):2905-12.
  18. Tang, X., et al., PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment. European Journal of Pharmaceutical Sciences, 2019, 127:161-74.
  19. Zaghmi, A., et al., Mechanisms of activity loss for a multi-PEGylated protein by experiment and simulation, Materials Today Chemistry, 2019, 12:121-31.
  20. Hernandez-Vargas, G., et al., Thermo-separating polymer-based aqueous two-phase systems for the recovery of PEGylated lysozyme species, Journal of Chromatography B., 2019, 1105:120-8.
  21. Abbasi, S., et al., Polyacrylamide–b-copolypeptide hybrid copolymer as pH-responsive carrier for delivery of paclitaxel: Effects of copolymer composition on nanomicelles properties, loading efficiency and hemocompatibility, Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2018.
  23. Peng, G., et al., N-terminal site-specific PEGylation enhances the circulation half-life of Thymosin alpha 1, Journal of Drug Delivery Science and Technology, 2019, 49:405-12.
  24. Pereira Gomes, C., et al., Fine tuning neuronal targeting of nanoparticles by adjusting the ligand grafting density and combining PEG spacers of different length, Acta Biomaterialia, 2018, V. 78, P. 247-259.
  25. Lin, S.Y., et al., Multifunctional PEGylated Albumin/IR780/Iron Oxide Nanocomplexes for Cancer Photothermal Therapy and MR Imaging, Nanotheranostics, 2018, 2(2), p.106.
  26. Mahou, R., et al., Injectable and inherently vascularizing semi-interpenetrating polymer network for delivering cells to the subcutaneous space, Biomaterials, 2017.
  27. Su, B., et al., Effect of Retro‐Inverso Isomer of Bradykinin on Size‐Dependent Penetration of Blood–Brain Tumor Barrier, Small, 2018.
  28. Zhang, J., et al., Real-time and in-situ monitoring of Abrin induced cell apoptosis by using SERS spectroscopy, Talanta, 2019, V. 195, P. 8-16.
  29. Xu, W., et al., PEGylated hydrazided gold nanorods for pH-triggered chemo/photodynamic/photothermal triple therapy of breast cancer, Acta Biomaterialia, 2018, V. 82, P. 171-183.
  30. Srivastava, I., et al., Surface chemistry of carbon nanoparticles functionally select their uptake in various stages of cancer cells, Nano Research, 2017, 1-6.
  31. Schaedel, L., et al., Microtubules self-repair in response to mechanical stress, Nature Mater., 2015, 14(11):1156-63.
  32. Bhajun, R., et al., A statistically inferred microRNA network identifies breast cancer target miR-940 as an actin cytoskeleton regulator, Scientific Reports, 2015, 5: 8336.
  33. Portran, D., Micropatterning Microtubules, Methods in Cell Biology, 2014, 39-51.
  34. Boujemaa-Paterski, R., et al., Directed actin assembly and motility, Methods Enzymol, 2014, 540: 283-300.
  35. Vignaud, T., et al., Polyacrylamide hydrogel micropatterning. Methods Cell Biol, 2014, 120: 93-116.
  36. Li, J., et al., Smart Asymmetric Vesicles with Triggered Availability of Inner Cell-Penetrating Shells for Specific Intracellular Drug Delivery, ACS Applied Materials & Interfaces, 2017.
  37. Zhou, Z., et al., Comparison of Site-Specific PEGylations of the N-Terminus of Interferon Beta-1b: Selectivity, Efficiency, and in Vivo/Vitro Activity. Bioconjugate Chemistry, 2013, 25(1): p. 138-146.
  38. Wu, Y., et al., Fabrication of thermo-sensitive complex micelles for reversible cell targeting, Journal of Materials Science: Materials in Medicine, 2015, 26:255.
  39. Wang, L, et al., Iron-engineered mesoporous silica nanocatalyst with biodegradable and catalytic framework for tumor-specific therapy, Biomaterials 2018, V. 163, P. 1-13.
  40. Yu, L., et al., Ultrasmall mesoporous organosilica nanoparticles: Morphology modulations and redox-responsive biodegradability for tumor-specific drug delivery, Biomaterials, 2018, V. 161, P. 292-305.
  41. Hu, Y., et al., Facile Construction of Mitochondria-Targeting Nanoparticles for Enhanced Phototherapeutic Effects, Biomaterials Science, 2017.
  42. Gonzalez-Villegas, J., et al., Poly (ethylene glycol)-modified zirconium phosphate nanoplatelets for improved doxorubicin delivery, Inorganica Chimica Acta, 2017.
  43. Limor Minai, et al., Optical Nanomanipulations of Malignant Cells: Controlled Cell Damage and Fusion, Small, 2012.
  44. Chen, Y., et al., An upconversion nanoparticle/Ru (ii) polypyridyl complex assembly for NIR-activated release of a DNA covalent-binding agent. RSC Advances, 2016, 6(28):23804-8.
  45. Farvadi, F., et al., Micellar stabilized single-walled carbon nanotubes for a pH-sensitive delivery of doxorubicin. Research in Pharmaceutical Sciences, 2014, 9(1):1-10.
  46. Badkas, A., et al., Modulation of in vitro phagocytic uptake and immunogenicity potential of modified Herceptin®-conjugated PLGA-PEG nanoparticles for drug delivery, Colloids and Surfaces B: Biointerfaces, 2018, V. 162, P. 271-278.
  47. Yang, C., et al., Effects of PEGylation on biomimetic synthesis of magnetoferritin nanoparticles, Journal of Nanoparticle Research, 2017, 19(3):101.
  48. Look, L., et al., Ligand-Modified Human Serum Albumin Nanoparticles for Enhanced Gene Delivery, Molecular Pharmaceutics, 2015, 12 (9), 3202-3213.
  49. Gossmann, R., et al., Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS–PAGE and LC–MS, European Journal of Pharmaceutics and Biopharmaceutics, 2015, V. 93, p. 80-87.
  50. Zhao, L., et al., An intraocular drug delivery system using targeted nanocarriers attenuates retinal ganglion cell degeneration. Journal of Controlled Release, 2017.
  51. Javanmardi, S., et al., Redox-Sensitive, PEG-Shielded Carboxymethyl PEI Nanogels Silencing MicroRNA-21, Sensitizes Resistant Ovarian Cancer Cells to Cisplatin, Asian Journal of Pharmaceutical Sciences, 2018.
  52. Brinkman, A.M., et al., Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer. Biomaterials, 2016, 101:20-31.
  53. Wang, X., et al., Polycation-telodendrimer nanocomplexes for intracellular protein delivery, Colloids and Surfaces B: Biointerfaces, 2018, V. 162, p. 405-414.
  54. Zhang, C., et al., Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase. PloS one, 2012, 7(6): e39659.
  55. Muddineti, O.S., et al., Vitamin-E/lipid based PEGylated polymeric micellar doxorubicin to sensitize doxorubicin-resistant cells towards treatment, Reactive and Functional Polymers, 2019, 134:49-57.

Founded in 2001 by experts in PEG synthesis and PEGylation, JenKem Technology specializes exclusively in the development and manufacturing of high quality polyethylene glycol (PEG) products and derivatives, and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified, and adheres to ICH Q7A guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to in-house polymerization from ethylene oxide, enabling facile traceability for regulated customers. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale.